✨ Free AI Report
vTv Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview vTv Therapeutics Inc.
Research Preview

vTv Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with its clinical pipeline led by cadisegliatin, currently...

Analyst-debate audio for vTv Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for vTv Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
vTv Therapeutics Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Transformative T1D opportunity with credible pathway to approval if Phase 3 cadisegliatin data meets expectations, positioned as...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-Stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest vTv Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

vTv Therapeutics Inc. Overview

Pro stress-test →

vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with its clinical pipeline led by cadisegliatin, currently in Phase 3 trial as a potential first-in-class oral glucokinase activator for type 1 diabetes treatment. The company is advancing toward a pivotal inflection point with topline data from the CATT1 Phase 3 trial expected in the second half of 2026.

Strategic Profile

Pro stress-test →

vTv Therapeutics is a subsidiary of MacAndrews & Forbes Incorporated, providing strategic backing. The company has license agreements with multiple partners including Reneo Pharmaceuticals, Anteris Bio, Cantex Pharmaceuticals, and Novo Nordisk, enabling a diversified pipeline approach across metabolic, inflammatory, and oncology indications.

Competitive Landscape

Pro stress-test →

vTv competes in the biopharmaceutical space developing oral small molecules for diabetes and chronic diseases. The company faces competition from established diabetes therapeutic developers and other clinical-stage biotech firms pursuing similar metabolic disease targets, but cadisegliatin's first-in-class positioning and FDA breakthrough designation provide competitive advantages if Phase 3 succeeds.

Industry Context

vTv Therapeutics Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development.

Key facts

Founded: 2015 · Headquarters: High Point, North Carolina, US · Employees: 11-50 · Revenue: $17K · Market cap: $100M

What the analysts stress-tested

The top findings that survived the multi-agent debate for vTv Therapeutics Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when vTv Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GLP-1 receptor agonists (semaglutide, tirzepatide)Established diabetes and weight management therapies; different mechanism than cadisegliatin→Other glucokinase activators in developmentCompeting approaches to glucokinase activation; cadisegliatin positioned as first-in-class oral→Insulin adjunctive therapiesComplementary approaches to improve type 1 diabetes glycemic control→

Compare vTv Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

vTv Therapeutics Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about vTv Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare vTv Therapeutics Inc. and its top competitor on Cyborg Score”
“What did vTv Therapeutics Inc. do this quarter?”
“Is vTv Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does vTv Therapeutics Inc. do?+
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with its clinical pipeline led by cadisegliatin, currently...
What is vTv Therapeutics Inc.'s Cyborg Score?+
vTv Therapeutics Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are vTv Therapeutics Inc.'s main competitors?+
Named competitors include GLP-1 receptor agonists (semaglutide, tirzepatide), Other glucokinase activators in development, Insulin adjunctive therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full vTv Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the vTv Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track vTv Therapeutics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score